Equities

StemRIM Inc

4599:TYO

StemRIM Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)356.00
  • Today's Change-11.00 / -3.00%
  • Shares traded53.70k
  • 1 Year change-46.71%
  • Beta1.8789
Data delayed at least 20 minutes, as of Nov 13 2024 06:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

StemRIM Inc. is a Japan-based company mainly engaged in the regenerative medicine business. The Company is engaged in the development and research of medicines based on new action mechanism to promote functional regeneration and healing of biological tissue damaged and lost function due to injury or illness. The Company’s main product is stem cell regeneration-inducing medicine. The stem cell regeneration-inducing medicine is a medicine which can obtain the same therapeutic effect as regenerative medicine only by administering the medicine without using living cells and tissues.

  • Revenue in JPY (TTM)0.00
  • Net income in JPY-2.02bn
  • Incorporated2006
  • Employees44.00
  • Location
    StemRIM Inc3F, Saito Bio-Incubator, 7-7-15, SaitoIBARAKI-SHI 567-0085JapanJPN
  • Phone+81 726487152
  • Websitehttps://stemrim.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Ohki Healthcare Holdings Co Ltd254.49bn1.28bn11.72bn632.008.930.38057.740.046193.2693.2618,553.592,189.151.829.593.36402,672,500.000.8751.853.768.424.996.160.4810.71780.8641--0.254713.929.925.301.281.51-5.345.92
CellSeed Inc199.47m-957.04m16.95bn35.00--7.73--84.96-30.72-30.726.4063.290.08921.657.915,699,172.00-42.79-49.69-46.02-54.5555.3863.66-479.79-428.6216.42-5,460.760.0651--50.39-28.62-11.43--80.73--
Stella Pharma Corp284.89m-726.61m17.02bn44.00--5.53--59.73-22.94-22.948.9190.490.0610.04332.596,474,773.00-15.55-22.50-16.34-24.8384.75---255.05-488.6517.82-563.580.217--17.65--1.94---5.87--
CanBas Co Ltd (Parent)0.00-1.21bn17.03bn11.00--6.86-----67.63-67.630.00129.880.00----0.00-53.54-62.25-56.62-70.91-------2,015.6225.09--0.00------2.77------
TAIKO PHARMACEUTICAL CO LTD6.28bn-2.34bn18.53bn208.00--2.28--2.95-46.93-46.93125.40160.660.4341.692.9430,201,920.00-16.12---19.68--55.73---37.15--2.83--0.2166--21.43--26.23------
Astena Holdings Co Ltd53.39bn2.09bn20.82bn1.40k9.650.70454.520.3952.6252.621,341.82721.110.79763.292.6938,024,920.003.122.495.764.4434.1125.333.912.320.879391.650.34944.924.73-2.85100.61-3.8538.5411.38
Oncolys Biopharma Inc31.38m-1.91bn22.55bn34.00--10.48--718.53-94.41-94.411.5386.360.0150.000.2917923,058.80-91.65-45.75-104.28-51.860.0060.46-6,093.40-233.669.72-102.930.1442---93.54-17.86-68.72--28.18--
StemRIM Inc0.00-2.02bn22.58bn44.00--2.54-----32.98-32.980.00144.570.00----0.00-20.44-8.34-20.74-8.49-------68.74131.03-11,344.720.00---100.00---1,301.17---4.35--
Fuso Pharmaceutical Industries Ltd57.72bn2.20bn24.87bn1.31k10.220.5935.550.4308257.39257.396,774.964,436.490.75813.072.3344,163,730.002.891.914.973.0926.5826.923.812.690.940650.750.26741.108.613.76-14.219.029.13-2.64
Fuji Pharma Co Ltd44.56bn6.36bn32.80bn1.62k5.060.71663.330.736261.79261.791,833.311,849.150.51561.403.1527,490,440.007.364.1011.635.5839.2842.4114.287.550.6276--0.391231.1715.421.5227.410.370919.045.73
Daito Pharmaceutical Co Ltd47.40bn3.23bn33.01bn1.07k10.370.63264.810.6966207.36207.363,045.213,400.430.61781.862.7644,294,390.003.906.275.088.2420.2822.656.328.471.29--0.189119.593.982.66-8.47-1.2711.3711.67
Data as of Nov 13 2024. Currency figures normalised to StemRIM Inc's reporting currency: Japanese Yen JPY

Institutional shareholders

0.90%Per cent of shares held by top holders
HolderShares% Held
Daiwa Asset Management Co. Ltd.as of 30 Jun 2024241.00k0.39%
Simplex Asset Management Co., Ltd.as of 03 Oct 2024165.40k0.27%
Mitsubishi UFJ Asset Management Co., Ltd.as of 29 Jun 202349.90k0.08%
Meiji Yasuda Asset Management Co. Ltd.as of 29 Nov 202235.00k0.06%
Schroder Investment Management (Japan) Ltd.as of 30 Jun 202432.00k0.05%
SSgA Funds Management, Inc.as of 03 Oct 202419.00k0.03%
Amundi Japan Ltd.as of 11 Sep 20233.70k0.01%
Connor, Clark & Lunn Investment Management Ltd.as of 30 Jun 20242.80k0.01%
LGT Capital Partners AG (Investment Management)as of 31 May 20242.50k0.00%
Schroder Investment Management Ltd.as of 30 Jun 20240.000.00%
More ▼
Data from 30 Jun 2024 - 31 Oct 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.